Physicians' Academy for Cardiovascular Education

Familial Hypercholesterolemia

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

A minority of FH patients is identified and labeled as such, which impacts treatment

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
##SCROLLER_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##SCROLLER_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##SCROLLER_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015
##SCROLLER_ITEMS_FULL_TITLE##

A new prediction tool to identify disease-causing mutations in familial hypercholesterolaemia

3' education - May 24, 2015 - ISA2015, Amsterdam - Joost Besseling
##SCROLLER_ITEMS_FULL_TITLE##

FH: Call for investigators to get involved

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Evan Stein
##SCROLLER_ITEMS_FULL_TITLE##

Homozygous FH: treatment challenges

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9-inhibitor less frequently administered may be effective treatment option

3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##SCROLLER_ITEMS_FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##SCROLLER_ITEMS_FULL_TITLE##

Screening for Familial Hypercholesterolaemia

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - dr. Kees Hovingh
##SCROLLER_ITEMS_FULL_TITLE##

Strong reduction CV events in FH patients with ApoB-inhibitor

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Paul Barton Duell
##SCROLLER_ITEMS_FULL_TITLE##

Unique Dutch collaborative effort to identify FH patients

3' education - Apr. 1, 2015 - Amersfoort, The Netherlands - Dr. Janneke Wittekoek
##SCROLLER_ITEMS_FULL_TITLE##

OSLER studies Compelling data on PCSK9 inhibition

3' education - Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##SCROLLER_ITEMS_FULL_TITLE##

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

3' education - Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein
##SCROLLER_ITEMS_FULL_TITLE##

2014: the major lipid developments in review

3' education - Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##SCROLLER_ITEMS_FULL_TITLE##

FH in Europe: Need for a registry

3' education - Nov. 10, 2014 - Zeist, The Netherlands - dr Kees Hovingh & Eric Bruckert
##SCROLLER_ITEMS_FULL_TITLE##

First European experience with human MTP-inhibitor in HoFH

10' education - Oct. 24, 2014
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9 inhibition: Clinical Update 2014

3' education - Oct. 29, 2014 - Snapshot 2014 - Dr Evan Stein
##SCROLLER_ITEMS_FULL_TITLE##

HoFH: New insights in prevalence and therapy

3' education - Oct. 26, 2014 - Snapshot 2014 - dr Kees Hovingh
##SCROLLER_ITEMS_FULL_TITLE##

HoFH: New insights and expanding therapeutic options

10' education - Sep. 6, 2014 - Snapshot 2014 - Dr. Kees Hovingh, AMC, Amsterdam, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

10' education - Sep. 3, 2014
##SCROLLER_ITEMS_FULL_TITLE##

Biology and validation of PCSK9 as a novel target to lower LDL-C

10' education - Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein

Identifying patients for PCSK9 therapy

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands
PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

Better characterization of ASCVD risk in children with FH by measuring Lp(a) levels

Literature - Jan. 7, 2019 - Zawacki et al. - J Clin Lipidol 2018

A retrospective review showed that children with FH and family history of early-onset ASCVD were more likely to have Lp(a) ≥50 mg/dL, compared with children with FH and family history of late-onset ASCVD.

Updated AHA/ACC cholesterol guidelines focus on more personalized risk assessment

AHA 2018 – Chicago, IL, USA

News - Nov. 11, 2018
The updated cholesterol guidelines help physicians to personalize treatment based on risk assessment, and now include CAC measurement to guide treatment decisions in certain patients.

AHA 2018 The updated cholesterol guidelines help physicians to personalize treatment based on risk assessment, and now include CAC measurement to guide treatment decisions in certain patients.

Final phase 3 study of bempedoic acid met safety and tolerability endpoints

News - Oct. 29, 2018

The CLEAR Wisdom randomized phase 3 trial (1002-047) showed bempedoic acid to be safe and well-tolerated in high CV risk patients on statins, as compared to placebo.

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA
Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

Clinical genetic testing provides improved diagnosis of FH

News - Aug. 13, 2018

An Expert Consensus Panel recommends that clinical genetic testing becomes standard care for patients with definite or suspicion of FH, as well as for their at-risk relatives, to improve risk stratification, diagnosis and early treatment.

Oral microsomal triglyceride transfer protein inhibitor is beneficial in HoFH

Literature - June 28, 2018 - Blom DJ, et al. - Orphanet J Rare Dis 2018
In patients with HoFH, lomitapide led to a significant reduction of LDL-c levels and to achievement of EAS targets in many patients, while CV event rates correlated with LDL-c levels.

In patients with HoFH, lomitapide led to a significant reduction of LDL-c levels and to achievement of EAS targets in many patients, while CV event rates correlated with LDL-c levels.

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa
Prof. Frederick Raal describes the prevalence and phenotypic variability of FH. Novel therapies have changed FH from a lethal disorder to a manageable dyslipidaemia.

Prof. Frederick Raal describes the prevalence and phenotypic variability of FH. Novel therapies have changed FH from a lethal disorder to a manageable dyslipidaemia.

PCSK9 RNA silencing agent now tested in multiple dyslipidemia populations

News - May 2, 2018

New ORION-data shows inclisiran has a one-size-fits-all dosing regimen of 300 mg on day 1, day 90 and every six months thereafter, across a wide range of dyslipidemia patients, including HoFH.

Conventional lipid-lowering therapy is not effective enough for heFH patients

Literature - May 1, 2018 - Hartgers ML et al., - J Clin Lipidol. 2018

A model assuming 100% adherence to maximal statin dose showed that only 10% of heFH patients with CHD would reach guideline-recommended LDL-c goal, and about half of those without CHD.

Total cholesterol levels determine survival in homozygous FH

Literature - Apr. 24, 2018 - Thompson GR - Eur Heart J 2018
In a retrospective survey of 133 patients with HoFH, the total serum cholesterol achieved by lipid-lowering therapies, was a major determinant of survival.

In a retrospective survey of 133 patients with HoFH, the total serum cholesterol achieved by lipid-lowering therapies, was a major determinant of survival.

A PCSK9 inhibitor lowers LDL-c in patients with gene mutations that are causative for FH

Literature - Apr. 5, 2018 - Hartgers ML, et al. - J Clin Lipidol 2018

A clinically meaningful LDL-c-lowering activity was observed in patients receiving alirocumab who are double or compound heterozygous, or homozygous for genes that are causative for FH.